Brief: First Toxicity Results From Scimitar Prospective Phase Ii Trial Signal Favorable Toxicity Profile Of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) For Prostate Cancer
10/03/2022 11:32
March 10 (Reuters) - ViewRay Inc VRAY.O :
* FIRST TOXICITY RESULTS FROM SCIMITAR PROSPECTIVE PHASE II
TRIAL
SIGNAL FAVORABLE TOXICITY PROFILE OF POST-PROSTATECTOMY
STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR PROSTATE CANCER
* VIEWRAY INC - POST-HOC ANALYSIS HIGHLIGHTS REDUCTION IN
GASTROINTESTINAL (GI) TOXICITY WITH MRIDIAN® MRI-GUIDED SBRT
COMPARED TO CT-GUIDED SBRT
Source text for Eikon: ID:nPn64mM2Ma
Further company coverage: VRAY.O
Recent news on Viewray
See all newsBrief: ViewRay Announces Commencement Of Nasdaq Delisting Proceedings Common Stock Expected To Begin Trading On The OTC Markets
Press Digest: Wall Street Journal - July 18
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
ViewRay hits record low on filing for voluntary Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global